Bladder Cancer

Avelumab Immunotherapy Approved for Bladder Cancer (05-15-2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy... Continue Reading

FDA Approves Imfinzi for Treatment of Urothelial Cancer (05-11-2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing... Continue Reading

FDA Approves Opdivo for Treatment of Bladder Cancer (02-16-2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing... Continue Reading

Tecentriq® Approved for Bladder Cancer (06-8-2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (06-8-2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers (03-14-2016)

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly... Continue Reading

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer (01-21-2016)

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium... Continue Reading

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (03-31-2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (03-30-2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (03-16-2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Next Page »